Published in final edited form as:

Mol Cancer Res. 2008 January ; 6(1): 151–164. doi:10.1158/1541-7786.MCR-07-0175.

Histone Modifications at the *ABCG2* Promoter following Treatment with Histone Deacetylase Inhibitor Mirror Those in Multidrug-Resistant Cells

Kenneth K.W. To, Orsolya Polgar, Lyn M. Huff, Kuniaki Morisaki, and Susan E. Bates

Molecular Therapeutics Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland

Abstract

ABCG2 is a ubiquitous ATP-binding cassette transmembrane protein that is important in pharmacology and may play a role in stem cell biology and clinical drug resistance. To study the mechanism(s) regulating *ABCG2* expression, we used ChIP to investigate the levels of acetylated histone H3, histone deacetylases (HDAC), histone acetyltransferases, and other transcription regulatory proteins associated with the *ABCG2* promoter. Following selection for drug resistance and the subsequent overexpression of *ABCG2*, an increase in acetylated histone H3 but a decrease in class I HDACs associated with the *ABCG2* promoter was observed. Permissive histone modifications, including an increase in histone H3 lysine 4 trimethylation (Me₃-K4 H3) and histone H3 serine 10 phosphorylation (P-S10 H3), were observed accompanying development of the resistance phenotype. These changes mirrored those in some cell lines treated with a HDAC inhibitor, romidepsin. A repressive histone mark, trimethylated histone H3 lysine 9 (Me₃-K9 H3), was found in untreated parental cells and cells that did not respond to HDAC inhibition with *ABCG2* up-regulation. Interestingly, although all five studied cell lines showed global histone acetylation and *MDR1* up-regulation upon HDAC inhibition, only those cells with removal of the repressive mark, and recruitment of RNA polymerase II and a chromatin remodeling factor Brg-1 from the *ABCG2* promoter, showed increased *ABCG2* expression. In the remaining cell lines, HDAC1 binding in association with the repressive Me₃-K9 H3 mark apparently constrains the effect of HDAC inhibition on *ABCG2* expression. These studies begin to address the differential effect of HDAC inhibitors widely observed in gene expression studies.

Introduction

ABCG2 is a ubiquitous ATP-binding cassette transmembrane protein that plays a significant role in absorption, distribution, and elimination of its substrate drugs (1–4). It also confers resistance in cancer cells to a variety of cancer chemotherapeutic agents such as mitoxantrone, topotecan, and methotrexate (5). *ABCG2* overexpression is frequently observed in human cancer cell lines selected with various anticancer drugs (6–10).

Little is known about the molecular mechanisms regulating *ABCG2* expression. The human *ABCG2* gene has a TATA-less promoter, with several Sp1, AP1, and AP2 sites and a CCAAT box downstream from a putative CpG island. To date, two functional *cis* elements

Copyright © 2008 American Association for Cancer Research.

Requests for reprints: Kenneth K.W. To, Molecular Therapeutics Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Building 10, Room 13N220, 10 Center Drive, Bethesda, MD 20892-4255. Phone: 301-496-0795; Fax: 301-402-1608. tok@mail.nih.gov.

Note: Supplementary data for this article are available at Molecular Cancer Research Online (<http://mcr.aacrjournals.org/>).

in the *ABCG2* promoter, namely the hormone (11) and hypoxia (12) response elements, and a peroxisome proliferator activated receptor response element upstream of the *ABCG2* gene (13) have been reported. We recently reported that DNA methylation plays a role in the regulation of human *ABCG2* in renal carcinoma cell lines (14). DNA methylation-mediated *ABCG2* silencing was associated with a coordinate modification (i.e., methylation and deacetylation) of histone H3 at lysine 9 bound to the promoter, causing alterations in chromatin structure. Interestingly, in the renal carcinoma cell line UOK181, despite the fact that the promoter was found to be unmethylated, basal *ABCG2* expression was only 2-fold higher than that in two *ABCG2* promoter-methylated cell lines. Moreover, we observed that *ABCG2* in UOK181 was significantly up-regulated by romidepsin (also known as depsipeptide or FK228), a histone deacetylase (HDAC) inhibitor. Thus, a DNA methylation-independent repression of *ABCG2* that is responsive to inhibition of HDACs is likely to exist. The activation of *ABCG2* by romidepsin at transcript and protein levels has been reported in both renal and colon cancer cell lines (15). However, the mechanisms underlying this activation have not been elucidated.

In eukaryotic cells, DNA is tightly packed in a highly organized chromatin structure. The packaging of DNA controls the interaction of regulatory proteins with their *cis* elements in the promoters of genes. Chromatin structure is modulated by the covalent modifications of the NH₂ termini of the core histones in nucleosomes and by the action of ATP-dependent chromatin remodeling complexes. In particular, histone acetylation at the promoter of genes has been shown to be necessary, albeit not sufficient, for transcriptional activation (16–18). Acetylation of histones neutralizes the positive charges on lysine residues and disrupts nucleosome structure, allowing unfolding of the associated DNA, access by transcription factors, and changes in gene expression. Acetylation of core nucleosomal histones is regulated by the opposing activities of histone acetyltransferases (HAT) and HDACs. Histone hyperacetylation is associated with active transcription whereas histone hypoacetylation is linked to transcriptionally silent chromatin. Chromatin fractions enriched in actively transcribed genes are abundant in the acetylated form of core histones (19).

For active transcription to occur, histone-modifying complexes are thought to cooperate with chromatin-remodeling complexes to establish a local chromatin environment that is permissive for the subsequent assembly of an active preinitiation complex at the promoter (20, 21). The major chromatin remodeling factors are the SWI/SNF ATP-dependent remodeling complexes. Upon recruitment to the promoter, they can alter chromatin structure by either shifting nucleosomes along the DNA or twisting DNA to modulate the nucleosome structure (22). Brg-1 and Brm are the two ATPase subunits of the SWI/SNF complex.

The aim of this study was to investigate the relevance of histone modifications to human *ABCG2* gene expression and the recruitment of transcription regulatory proteins to the *ABCG2* promoter in multidrug-resistant cells. We used the chromatin immunoprecipitation (ChIP) assay to map the region of histone hyperacetylation and recruitment of other transcription factors at the human *ABCG2* promoter in *ABCG2*-overexpressing multidrug-resistant cell lines and in some cancer cell lines selected from the National Cancer Institute drug screen, expressing various levels of *ABCG2*. We compared the effects of HDAC inhibition on the promoter with those resulting from selection for drug resistance. The data show that the characteristic pattern of histone acetylation at the *ABCG2* promoter was altered following *in vitro* selection of drug resistance and after treatment with romidepsin, a HDAC inhibitor currently in clinical trials. Other histone modifications were also observed in these settings, consistent with a histone code that facilitates the up-regulation of *ABCG2* in the cells.

Results

Transcriptional Up-Regulation of ABCG2 in Drug-Resistant Cell Lines

ABCG2 is expressed at varying levels in unselected cell lines and is highly overexpressed in drug-selected cells at both mRNA and protein levels (Fig. 1). To evaluate the role of promoter activity in the up-regulation of *ABCG2* in unselected and selected cell lines, a series of 5' deletion reporter gene constructs were generated from the *ABCG2* promoter with the 3' end terminating at +396 bp (14). Bailey-Dell et al. (23) showed that reporter activity roughly paralleled the relative level of *ABCG2* expression in their studies of choriocarcinoma cell lines. This suggested that basal expression was mediated to some extent by transactivating factors binding to the promoter. To study the possible contribution of transactivating factors in drug resistance, we evaluated the S1MI80 subline, which overexpresses *ABCG2* without gene amplification. We transfected parental and drug-resistant cells with the *ABCG2* promoter-luciferase reporter constructs. Compared with parental S1 cells, reporter activity driven by the various *ABCG2* promoter fragments was increased 8- to 10-fold in the resistant S1MI80 cells (Supplementary Fig. S1A and S1B). This increase in reporter activity is actually modest when compared with the overwhelming up-regulation of *ABCG2* in the resistant S1MI80 cells. Moreover, there was a generalized up-regulation of the reporter constructs in S1MI80 cells; we were not able to narrow down to a particular promoter region that contributes to the highest up-regulation. To this end, a DNA footprinting analysis was done in an attempt to identify the DNA sequences that could be involved in the up-regulation of *ABCG2* in the resistant S1MI80 cells. However, a convincing evidence of differential transcription factor binding between the parental and resistant cells could not be obtained (data not shown).

Transcriptional Activation of the ABCG2 Promoter by Romidepsin

The modestly increased transactivation activity noted in the reporter assay and the lack of an identifiable difference in DNA footprinting led us to seek other methods for explaining *ABCG2* overexpression, particularly in the S1MI80 cells lacking gene amplification. We thus explored a model system for the study of transactivation in which endogenous *ABCG2* expression is acutely induced and, therefore, not subject to potential genetic changes. Previous observations revealed that *ABCG2* expression is up-regulated in cells treated with romidepsin, a HDAC inhibitor (14, 15). *ABCG2* mRNA (Fig. 2A) and protein levels (Fig. 2B) were induced by romidepsin supplemented with 5 µg/mL of verapamil upon 24 h treatment in S1 cells in a dose-dependent manner. Verapamil, a P-glycoprotein inhibitor, was used to prevent the efflux of romidepsin by P-glycoprotein that is expressed in the cells. A dose of 20 ng/mL of romidepsin, which gave rise to a consistent up-regulation of *ABCG2* without significant cell death, was selected for further studies. Moreover, the increase in *ABCG2* mRNA induced by romidepsin was blocked by actinomycin D (Fig. 2C), suggesting that romidepsin regulates *ABCG2* mRNA levels through an effect on *ABCG2* transcription.

Accumulation of Acetylated Histones in the Chromatin of the ABCG2 Gene in Romidepsin-Treated S1 and in the Resistant S1MI80 Cells

Because *ABCG2* can be up-regulated by romidepsin, a HDAC inhibitor, we postulated that histone acetylation was involved in the activation of *ABCG2*. The levels of acetylated histone H3 and H4 (AcH3 and AcH4, respectively) were determined by immunoblot analysis and their association with different segments of the *ABCG2* promoter was examined using the ChIP assay. ChIP assays measure the interaction of protein with DNA in a given chromatin region *in vivo* (24).

As shown in Fig. 2B, global levels of histone H3 and H4 acetylation were increased by romidepsin treatment, even at the lowest concentration used (2 ng/mL). Histone acetylation

may have been saturated at higher concentrations of romidepsin because acetylation levels did not show any further increase in a dose-dependent manner. In contrast, global acetylation of histone H3 and H4 in the resistant cells was not higher than in the parental cells (Fig. 2B).

ChIP assays were done to evaluate modifications specific to the *ABCG2* promoter. Higher levels of promoter-associated histone H3 acetylation were observed in both romidepsin-treated and drug-resistant cells, compared with the untreated parental cells. DNA purified after immunoprecipitation with anti-AcH3 and AcH4 antibodies was evaluated by PCR using primers targeting the proximal (P1–P4; nt –687 to +20) and distal regions (nt –1,527 to –1,268) of the *ABCG2* promoter (Fig. 3A), and the promoter region of *GAPDH* where RNA polymerase II (Pol II) binds (ChIP assay kit manual from Active Motif). The relative amount of promoter-associated acetylated H3 and H4 was quantified by measuring the PCR band intensity in a molecular imager followed by normalization with the input. Serial dilutions of the input DNA were amplified by PCR to determine the linearity of the PCR reactions (Supplementary Fig. S2). The levels of PCR amplifications for all ChIP samples were within this linear range. No signal was obtained from immunoprecipitated samples if normal IgG was used (Fig. 3B). The proximal promoter fragment evaluated by ChIP includes three putative AP1 and seven Sp1 binding sites, and includes the putative minimal promoter for *ABCG2* (23). Romidepsin treatment induced hyperacetylation of histone H3 in all four regions of the proximal *ABCG2* promoter tested in S1 parental cells (Fig. 3B and C). No significant change in AcH4 was observed, but the basal levels were much higher than those for H3. The increase in Ac-K9,14 H3 in the P3 and P4 regions was found to be the most pronounced, at ~4 and 6-fold, respectively, where basal acetylation levels were the lowest. Surprisingly, the resistant S1MI80 cells also exhibited hyperacetylation of histone H3 on the proximal *ABCG2* promoter (P1–P4), and at 10-fold over control in P3, an even greater extent than in romidepsin-treated cells. Of note, the subregions within the proximal promoter (i.e., P1, P2, P3, or P4) were analyzed separately despite the fact that they cannot be precisely resolved by the ChIP assay. This serves to show the reproducibility of the ChIP analyses for the proximal promoter. In contrast, the enrichment of acetylated H3 in the distal region remained essentially unchanged after romidepsin treatment and in the resistant cells, confirming the specificity of histone H3 acetylation in the *ABCG2* promoter (Fig. 3B and C). Consistent differential results between the distal and the proximal (P1–P4) regions indicated that the developed ChIP assay allowed precise analysis of contiguous DNA regions positioned at distances <1,000 bp. As an internal control, histone H3 and H4 acetylation levels at the constitutive *GAPDH* promoter were also analyzed. The considerable acetylated H3 and H4 binding to the *GAPDH* promoter did not change upon romidepsin treatment or in the resistant cells. Notably, *GAPDH* gene expression did not respond to romidepsin treatment, as shown in Fig. 2A. The proximal promoter region P3 was chosen for all subsequent ChIP analyses because of a more reproducible and consistent increase in promoter-associated AcH3 upon romidepsin treatment and in resistant cells. Region P4 showed greater variability in this respect.

Release of HDACs from and Recruitment of RNA Pol II to the *ABCG2* Promoter Upon Its Activation

Next, we used the proximal promoter P3 region as a probe for alterations in RNA Pol II, HDACs, and HATs bound to the *ABCG2* promoter, using antibodies specific for Pol II, HDACs, p300, or GCN5, in control, romidepsin-treated, and S1MI80 cells. Immunoprecipitation of the *ABCG2* chromatin using antibodies against HDAC1, HDAC3, HDAC6, and HDAC8 revealed the association of these HDACs, with different affinity, to the proximal and distal *ABCG2* promoters (and the control *GAPDH* promoter) in the untreated parental cells (Fig. 4A and B). The association of HDAC1 and HDAC3 with the

proximal *ABCG2* promoter was significantly reduced in romidepsin-treated S1 cells and in the S1MI80-resistant cells, compared with that in the untreated parental S1 cells, suggesting that release of these HDACs was associated with promoter activation. HDAC8 bound weakly to the proximal *ABCG2* promoter in the untreated parental S1 cells, and this binding was decreased in resistant S1MI80 cells (but not in romidepsin-treated S1 cells). However, the binding of HDAC1, HDAC3, and HDAC8 to the distal *ABCG2* promoter region was identical in all three groups (parental, resistant, and romidepsin-treated). In contrast, HDAC6 bound constitutively to both the proximal and distal *ABCG2* promoter and the binding was not affected upon romidepsin treatment and in the resistant cells. Anti-HDAC2 antibody did not result in immunoprecipitation of the *ABCG2* promoter from any samples. To show the reproducibility of the ChIP assays, especially for the proximal *ABCG2* promoter, the association of HDAC1, HDAC2, and HDAC3 and AcH3 with different *ABCG2* promoter regions and the *GAPDH* promoter is shown in Supplementary Fig. S3. The binding of Pol II, an indicator of *ABCG2* promoter activity, to the proximal promoter in the untreated parental S1 cells was only barely detectable. In contrast, there was more Pol II binding to the P3 region in the romidepsin-treated cells (3-fold) and even more in the resistant S1MI80 cells (8-fold; Fig. 4A and B). Of note, we observed considerable Pol II binding at the *ABCG2* distal promoter region in untreated S1 cells and it remained unchanged in romidepsin-treated and drug-resistant cells. These results suggested that *ABCG2* gene expression correlates with the presence of Pol II at the proximal promoter of the *ABCG2* gene. For the HATs, both p300 and GCN5 were found binding to the distal and the proximal P3 regions, and not changing in romidepsin-treated or in the drug-resistant cells (Fig. 4A and B). In the *GAPDH* control, Pol II, p300, and GCN5 bound strongly to the *GAPDH* promoter, whereas the HDACs (except HDAC6) were only weakly bound (Fig. 4A and B). Further, their association with the promoter was not different in the untreated parental S1, romidepsin-treated S1, or resistant S1MI80 cells.

Global levels of these HDACs and HATs were also examined in whole-cell lysates to show that the observations were not due to global nonspecific events. In contrast to the promoter-specific effects, levels of HDAC1, HDAC3, and HDAC8 were found to be similar in the parental, romidepsin-treated S1, and resistant S1MI80 cells upon immunoblot analysis (Fig. 4C).

Taken together, the results indicate that site-specific histone H3 hyperacetylation, reduced association of HDAC1 and HDAC3 (HDAC8, also, in the resistant S1MI80 cells), and recruitment of Pol II at the *ABCG2* proximal promoter correlates with the transcriptional activation of *ABCG2* in both romidepsin-treated and resistant cells.

Other Histone Modifications at the *ABCG2* Promoter in Drug-Resistant S1MI80 Cells

In a previous study, we showed that the activation of *ABCG2* in methylated renal carcinoma cell lines was associated with the switching of histone modification from methylation to acetylation at lysine 9 on histone H3 (14). We thus asked whether the hyperacetylation of histone H3 and the corresponding up-regulation of *ABCG2* in the resistant S1MI80 and romidepsin-treated S1 cells were accompanied by specific histone modifications at the *ABCG2* promoter.

We first examined the global levels of histone modifications in parental cells upon romidepsin treatment; in the resistant cells, histone modifications were examined and compared with the untreated parental S1 by immunoblot analysis with a panel of antibodies against various modified forms of histone H3. As shown in Fig. 5A, romidepsin treatment remarkably increased the global level of Ac-K9,14 H3, increased only slightly that of Me₃-K4 H3, did not affect Me₃-K9 H3, but decreased the level of P-S10 H3 to nearly undetectable levels. The significant repression of the global histone H3 Ser-10

phosphorylation by an HDAC inhibitor has been previously reported in human leukemia cells lines (25) and in mouse oocytes during meiosis (26), where romidepsin and trichostatin A, respectively, led to significant histone H3 Ser-10 dephosphorylation. In fact, histone H3 Ser-10 dephosphorylation is linked to the pro-metaphase arrest resulting from HDAC inhibitor treatment (27). Compared with the parental S1 cells, the resistant S1MI80 cells have higher global levels of Me₃-K4 H3 but similar levels of Ac-K9,14 H3 and Me₃-K9 H3. The global level of P-S10 H3 was slightly increased in S1MI80 cells.

ChIP analysis of the *ABCG2* promoter resulted in distinctly different patterns of the histone marks compared with global histone modifications (Fig. 5B and C). There was a strong correlation among the patterns of histone acetylation and methylation with *ABCG2* expression. Elevated levels of Ac-K9,14 H3, Me₃-K4 H3, and P-S10 H3 have been linked to a permissive chromatin state that favors active transcription (28–33). Compared with the parental S1 cells, a consistent and robust increase in these permissive histone modifications were observed at the proximal *ABCG2* promoter in the romidepsin-treated S1 cells and in the S1MI80-resistant subline (Fig. 5B and C). The increased histone H3 S10 phosphorylation at the *ABCG2* promoter is remarkable in the face of reduction in the global H3 S10 phosphorylation level as noted above. On the other hand, a significantly lower level of Me₃-K9 H3, a modification that marks silent heterochromatin (34–36), was found at the *ABCG2* promoter, particularly in the resistant cells.

As a control, analysis of histone modifications at the *GAPDH* promoter was also conducted. Not surprisingly, given its ubiquitous expression, high levels of the permissive histone modifications (Ac-K9,14 H3 and Me₃-K4 H3) but minimal levels of a repressive histone modification (Me₃-K9 H3) were detected in the *GAPDH* promoter (Fig. 5B). Consistent with its selection as a control gene, the histone modifications at the *GAPDH* promoter were similar in romidepsin-treated and resistant cells, compared with the parental cells.

Inhibition of HDACs by Romidepsin Did Not Up-Regulate *ABCG2* in All Cell Types

Taken together, the results above show that romidepsin is able to up-regulate *ABCG2* in S1 cells through gene-specific alterations of chromatin, particularly an increase in Ac-K9,14 H3, Me₃-K4 H3, and P-S10 H3, but a decrease in Me₃-K9 H3. Similar changes were observed in drug-resistant cells (S1MI80) and combined with the enhanced transactivating activity noted in Supplementary Fig. S1 may begin to explain the up-regulation of *ABCG2* in S1MI80. We next examined histone modifications in a number of other cell lines and their drug-resistant counterparts. We first asked whether *ABCG2* induction was a universal response to treatment with an HDAC inhibitor. S1, H460, MCF-7, SF295, and SW620 cells were treated with a range of different doses of romidepsin (0–30 ng/mL) for 24 h. Again, verapamil was added to prevent P-glycoprotein expression from limiting the effect of romidepsin. As a control, *MDR1* expression was also assessed because it has been found to be activated in a number of different cell types by HDAC inhibitors, including sodium butyrate, trichostatin A, and romidepsin (15, 37–39). As depicted in Fig. 6, romidepsin induced a dose-dependent up-regulation of *MDR1* in all cell lines tested. A dose-dependent increase in *ABCG2* was also noted in S1 and H460 cells. In contrast, *ABCG2* expression was down-regulated in MCF-7 and SF295 and not altered in SW620 after romidepsin treatment, despite the fact that a consistent activation of *MDR1* was observed in these cell types. In a previous study, we showed that *ABCG2* promoter methylation could constrain gene induction in response to romidepsin treatment (14); it should be noted that the *ABCG2* promoter was unmethylated in all cell lines used in this study (data not shown). Thus, at doses readily capable of up-regulating *MDR1*, romidepsin did not induce *ABCG2* in all cell lines. Why *ABCG2* was repressed in MCF-7 and SF295 upon romidepsin treatment is not clear. However, repression of selected genes has been observed following HDAC inhibitor

treatment (40). The cell type-specific changes in *ABCG2* did allow us to look at the specific changes at the *ABCG2* promoter in this study.

Permissive and Repressive Histone Modifications at the *ABCG2* Promoter Parallel *ABCG2* Expression

To explore the failure of romidepsin to up-regulate *ABCG2* in MCF-7, SF295, and SW620 cells following its treatment, we examined histone modifications following romidepsin. Global histone acetylation was increased in every cell line tested (Supplementary Fig. S4). ChIP assays were thus done on the *ABCG2* promoter to determine whether the pattern of histone modification was altered after romidepsin. There was an increase in Ac-K9,14 H3 at the proximal *ABCG2* promoter in all five cell lines (Fig. 7A and B). Although this was a permissive modification, it was not sufficient to support *ABCG2* up-regulation. Elevation of the permissive modification Me₃-K4 H3 and reduction in the repressive mark Me₃-K9 H3 at the proximal promoter were observed only in S1 and H460 cells, which directly correlated with the induction of *ABCG2*. Also observed in Fig. 5, increased P-S10 H3 was noted in S1 cells treated with romidepsin. In contrast, changes in these histone modifications (i.e., Me₃-K4 H3, Me₃-K9 H3, and P-S10 H3) were not observed in cells that did not show *ABCG2* induction following romidepsin treatment (i.e., MCF-7, SF295, and SW620 cells; Fig. 7A and B). There was a perfect match between these histone marks and gene induction following romidepsin treatment. These results show that inhibition of HDACs alone is insufficient to alter the transcription-repressive pattern of histone modification (i.e., Me₃-K9 H3; Fig. 7A and B) present in the untreated cells. Interestingly, compared with the parental cells, the pattern of histone modifications favoring gene activation (i.e., increase in Me₃-K4 H3 and decrease in Me₃-K9 H3) found in S1MI80-resistant cells was also shown in the *ABCG2*-overexpressed drug-selected resistant H460 MX20, MCF-7 FLV1000, and SF295 MX2000 sublines examined in our study.

ABCG2 Up-Regulation Is Not Due to Histone Loss from the Promoter

A recent study reported that nucleosome loss occurs at many active promoters and is proportional to the transcription initiation rate (41). In another study, the nucleosome loss from the *PHO5* promoter associated with its transcriptional activation is preceded by a transient increase in histone H3 acetylation (42). To determine whether *ABCG2* up-regulation in the resistant cells and in romidepsin-treated S1 and H460 cells was associated with histone loss and to verify the accuracy of the estimate of histone modifications shown in Fig. 7, occupancy of total and unmodified histone H3 at the *ABCG2* promoter was determined by ChIP assays using antibody against the COOH terminus of histone H3. Neither romidepsin-treated cells nor resistant cells showed a loss of total histone H3 at the *ABCG2* promoter (Supplementary Fig. S5).

Factors Associated with the Responsive and Unresponsive *ABCG2* Gene after Romidepsin Treatment

To explore further the epigenetic factors determining *ABCG2* response to romidepsin treatment, a panel of candidate proteins was examined for their differential association with either the responsive or unresponsive *ABCG2* promoter by ChIP (Fig. 8) and their global expression by immunoblot analysis (Supplementary Fig. 6). As depicted earlier in S1 cells (Fig. 4), the induction of *ABCG2* was correlated closely with the increased association of Pol II at the proximal promoter, which was only observed in those cell lines whose *ABCG2* could be up-regulated by romidepsin (i.e., S1 and H460). Similarly, in these lines, an increased association of the chromatin remodeling factor known to be associated with the SWI/SNF complex, Brg-1, to the *ABCG2* promoter was consistently observed. Finally, a significant reduction of HDAC1 and Sp1 association with the *ABCG2* proximal promoter was observed in S1 and H460 cells following romidepsin treatment. These are likely to be

critical differences, given that in cells that do not respond to romidepsin treatment (i.e., MCF-7, SF295, and SW620), no significant difference in the association of HDAC1, Sp1, Brg-1, or Pol II with the *ABCG2* promoter was found following romidepsin treatment. Thus, the persistence of HDAC1 and Sp1 binding, and the lack of Brg-1 association with the promoter, seem to be involved in the romidepsin unresponsiveness of *ABCG2* in MCF-7, SF295, and SW620.

Discussion

Overexpression of the *ABCG2* gene is frequently found in cancer cell lines selected with a number of anticancer drugs, including mitoxantrone, topotecan, SN-38, or flavopiridol (6–10). However, little is known about the mechanisms underlying its up-regulation. Earlier studies identified gene amplification and chromosome translocation as mechanisms for the increased expression of the *ABCG2* gene in drug-resistant cell lines (43). The use of alternative 5' promoters at the *ABCG2* gene in drug-selected cells may offer another novel mechanism of *ABCG2* up-regulation (44), a finding similar to observations in *MDR-1* where rearrangement of the 5' region of *MDR-1* resulted in capture of that gene by another promoter (45). In this study, we examined epigenetic mechanisms for the overexpression of *ABCG2* in multidrug-resistant cell lines and in unselected cell lines treated with a HDAC inhibitor. This includes the hyper-acetylation of histone H3 (K9,14) at the proximal *ABCG2* promoter, the concomitant increase in trimethylation of histone H3 (K4), and the decrease in trimethylation of histone H3 (K9).

Using a series of *ABCG2* promoter-luciferase reporter gene vectors with progressive NH₂ terminus deletion, our study was initiated with an aim to identify promoter sequences necessary for transactivation of *ABCG2*. A modest increase in trans-activation was observed in the resistant S1MI80 cells, compared with the parental S1 cells. However, the reporter assay failed to identify 5'-flanking sequence *cis*-elements involved in the preferential expression of *ABCG2* in S1MI80 cells. To this end, DNA footprinting experiments done using S1 and S1MI80 cell lysates did not offer convincing differential transcription factor binding (data not shown). Thus, we turned to an inducible system to identify regulatory elements relevant for *ABCG2* activation.

The HDAC inhibitor romidepsin has been shown to activate *ABCG2* expression in a number of cell lines (14, 15) and actinomycin D pretreatment confirmed an effect at the level of RNA transcription. We examined the chromatin modifications occurring at the *ABCG2* promoter by ChIP assay (24). First, we showed a significant and specific increase in histone acetylation at the proximal *ABCG2* promoter both in resistant S1MI80 cells and in parental S1 cells upon treatment with romidepsin. This increase in histone acetylation occurred concurrently with RNA Pol II binding to the proximal *ABCG2* promoter, marking it as transcriptionally active. The region studied corresponds to the region of the *ABCG2* promoter previously reported to have the highest activity in promoter fragment studies (23). A decrease in the amount of class I HDACs (HDAC1 and HDAC3; HDAC8 also in resistant S1MI80 cells) and Sp1 specifically associated with the proximal *ABCG2* promoter was observed in both resistant S1MI80 cells and parental S1 cells following romidepsin treatment. Because Sp1 is known to recruit HDAC1, the two probably come off from the promoter together (46). HDAC1 is thought to repress gene transcription through both deacetylation of core histones and deacetylation of various transcription factors (47). The increased acetylation of a gene promoter encoding a drug resistance transporter has also been observed for *MDR-1* following selection in doxorubicin or etoposide (48). Histone hyperacetylation of *MDR-1* was also noted following treatment with the HDAC inhibitor trichostatin A and some chemotherapeutic agents, including daunorubicin and etoposide (49). HDAC6, another HDAC investigated in this study, was found constitutively binding to

both proximal and distal *ABCG2* promoter and the *GAPDH* promoter and its binding was not affected by romidepsin treatment or by selection for drug resistance. HDAC6 is a subtype of the HDAC family that deacetylates α -tubulin. The reason for its constitutive promoter binding is unknown. Nonetheless, the inclusion of the data for HDAC6 illustrates the specificity and significance of reduced HDAC1 and HDAC3 binding to the proximal *ABCG2* promoter in the up-regulation of *ABCG2*. On the other hand, all the HATs (p300 and GCN5) studied bound constitutively to the *ABCG2* promoter and the binding was not affected by romidepsin treatment or by the development of drug resistance. The constitutive binding can be accounted for by the fact that these HATs do form a large complex with other components of the basal transcriptional machinery and they also form indirect association with chromatin via various histone-binding proteins. Taken together, the results indicate that the dissociation of HDAC complexes rather than the recruitment of more HATs was important to facilitate histone hyperacetylation at the proximal *ABCG2* promoter to up-regulate *ABCG2*. Furthermore, dissociation of the HDAC complexes (including HDAC1, HDAC2, and Sp1) seems to be a prerequisite for gene induction, as cell lines without *ABCG2* gene induction after romidepsin treatment showed none of these findings.

Although acetylation and deacetylation of histone proteins have been shown to induce a relaxed and competent or a condensed and inactive chromatin, respectively (50, 51), methylation of histones at key lysine residues seems to act cooperatively to generate a specific histone code to determine the chromatin configuration and thereby the transcriptional state (52–55). Specifically, methylation of histone H3 at lysine 4 is usually enriched at active hyperacetylated euchromatin domains, and is proposed to have a pivotal role in gene activation by providing a binding platform for different transcription factors (32). On the other hand, trimethylation of H3 at lysine 9 (Me₃-K9 H3) has been associated with silent hypoacetylated heterochromatin regions and is considered a repressive mark. In our study, ChIP assays revealed fairly high levels of Me₃-K9 H3 at the *ABCG2* promoters of all the untreated parental cell lines tested. The up-regulation of *ABCG2* in resistant cells and in some parental cells treated with romidepsin tracked closely with reductions of this repressive histone modification in the promoter. This was accompanied by a stronger association of permissive histone marks, Me₃-K4 H3 and P-S10 H3 (the latter for S1 cells only), with the *ABCG2* promoter. Active transcription was favored by this histone code, as evidenced by the increased binding of RNA Pol II to the same promoter region. Control experiments showed that the increase in chromatin accessibility over that region could not be explained by nucleosome loss and supported the importance of histone modifications at the *ABCG2* proximal promoter. Taken together, the results show that activation of *ABCG2*, whether due to drug selection and chronic overexpression or to treatment with an HDAC inhibitor, is associated with acetylation of histone H3, enhancement of permissive histone marks, reduction of repressive histone marks, increased RNA Pol II binding, and reduced HDAC1 and Sp1 binding. These findings are consistent with results observed at promoters of other activated genes (16, 17, 28, 34).

We have previously observed the induction of *ABCG2* mRNA by romidepsin in colon and renal cancer cell lines (15). Among the five cancer cell lines selected for this study, romidepsin induced *ABCG2* mRNA expression in two cell lines, S1 and H460, but not in the others, MCF-7, SF295, and SW620. Inhibition of HDAC resulted in both global and *ABCG2* promoter-specific histone H3 hyperacetylation in all five cancer cell lines. Intriguingly, *MDR1* mRNA encoding the ABC transporter P-glycoprotein was consistently induced as well. Thus, *MDR1* induction seems to be much more general than *ABCG2* induction. In MCF-7, SF295, and SW620 cells, inhibition of HDACs is not sufficient to generate the same pattern of transcription-permissive histone modifications, or to activate *ABCG2*. Changes toward the permissive histone marks at the *ABCG2* promoter (i.e., an increase in Me₃-K4 H3 and P-S10 H3; a decrease in Me₃-K9 H3) did not occur after

romidepsin treatment. Notably, Me₃-K4 H3 is more efficiently acetylated by known HATs than the unmodified one (56), thereby reinforcing the histone hyperacetylation. Thus, the lack of Me₃-K4 H3 at the *ABCG2* promoter in MCF-7, SF295, and SW620 after romidepsin treatment may have prohibited the up-regulation of *ABCG2*. At least in yeast, it has been shown that increased histone acetylation at promoters is not sufficient for enhanced transcription by transcriptional activators (57). Moreover, a recent study reported that a combination of high H3 acetylation (Ac-K9,14 H3) and H3 K4 methylation (Me₃-K4 H3) levels define distinct euchromatin regions allowing for stable expression of an integrated transgene (58). Integration into a region that is poor in or lacking Ac-K9,14 H3 and Me₃-K4 H3 conferred progressive silencing of the transgene. Figure 9 presents a schematic detailing the proposed epigenetic code involving the *ABCG2* promoter.

To further explore the epigenetic factors determining *ABCG2* expression, a panel of candidate proteins was examined for their differential association with either responsive or unresponsive *ABCG2* promoter upon romidepsin treatment. The transcriptional repressor HDAC1, after romidepsin treatment, remained in association with the unresponsive *ABCG2* promoter in MCF-7, SF295, and SW620 cells, but not with the activated *ABCG2* promoter in S1 and H460 cells (Fig. 8). In addition, an increased association of the chromatin remodeling factor, Brg-1, to the *ABCG2* promoter was observed consistently in S1 and H460 cells where *ABCG2* expression was activated by romidepsin treatment (Fig. 8). Brg-1, containing bromodomains, is thought to bind to acetylated histone tails with high affinity (51). It has been proposed that the Me₃-K4 H3 permissive mark (present at the activated *ABCG2* promoter in S1 and H460) could serve as additional interaction surface for Brg-1 (56).

In summary, we have shown that the *ABCG2* promoter has a reproducible pattern of histone modification that is altered following *ABCG2* overexpression due to the development of drug resistance or due to HDAC inhibition. Increased levels of permissive histone marks are accompanied by reduced levels of repressive marks. Our data strongly suggest that these histone modifications play an important role in the regulation of *ABCG2* expression in multidrug-resistant cells. Further, unlike *MDR1*, the induction of *ABCG2* following romidepsin exposure is cell line specific, a finding likely due to differences in the components of the repression complexes present at the gene regulatory region in a given cell line. It is intriguing that certain cell types respond to HDAC inhibition with increased histone acetylation but without *ABCG2* gene induction. Whereas differential display (59) or microarray analyses (60, 61) identify only 2% to 10% of expressed genes as sensitive to HDAC inhibitors, in this case, we have a gene responding to HDAC inhibition in one cell line but not in another. The factors that govern these differential responses have not been determined, but the *ABCG2* promoter studies presented here provide a platform for evaluating such factors. It will be important to determine whether the failure to respond to HDAC inhibitors lies in their lack of access to gene-specific HDACs or, once binding is accomplished, a failure to manipulate the regulatory complex. The data presented here clearly show that romidepsin is able to bind and inhibit HDACs elsewhere in the cells. Understanding the differential effects may reveal the dominant epigenetic mechanisms associated with *ABCG2* expression and potentially provide insight into strategies needed to accomplish the induction of therapeutically important genes by HDAC inhibition. Multiple cancer treatment strategies have been proposed, exploiting the unique effects of HDAC inhibition on gene induction. Examples include the improved therapeutic target that could result from induction of CD25 for sensitization of cells to interleukin 2-targeted therapy such as denileukin diftitox (62), cancer antigens for immuno-therapy (63), and the sodium-iodine symporter for transport of radioactive iodine (64). This line of investigation may also lead to understanding why some malignancies are very sensitive to HDAC inhibitors

whereas others are not, and for understanding drug resistance mediated by epigenetic changes.

Materials and Methods

Tissue Culture

Human colon cancer cell line S1 and its resistant subline S1MI 80 have been described previously (8). SW620, MCF-7, H460, and SF295 cells were chosen from the National Cancer Institute Tumor Drug Screen for this study. MCF-7 FLV1000, H460 MX20, and SF295 MX2000 were resistant sublines developed from their parental counterparts by stepwise selection in increasing concentrations of selecting agent and maintained in 1,000 nmol/L flavopiridol, 20 μ mol/L mitoxantrone, and 2,000 μ mol/L mitoxantrone, respectively. The cell lines were maintained in IMEM (S1, S1MI80, MCF-7, and MCF-7 FLV1000) or RPMI medium (SW620, SF295, SF295 MX2000, H460, and H460 MX20) supplemented with 10% fetal bovine serum, 100 units/mL streptomycin sulfate, and 100 units/mL penicillin G sulfate, and incubated at 37°C in 5% CO₂.

Drug Treatment

To test the effect of HDAC inhibition on *ABCG2* expression, cells were treated with 2, 5, 10, 20, or 30 ng/mL of romidepsin (also known as depsipeptide, FR901228, or NSC630176; Developmental Therapeutics Program, National Cancer Institute) supplemented with 5 μ g/mL of verapamil (Sigma) for 24 h. Verapamil was added to prevent the efflux of romidepsin mediated by P-glycoprotein up-regulation. Stock solutions of romidepsin and verapamil were dissolved in DMSO and water, respectively. For the inhibition of RNA synthesis study, S1 cells were treated with 5 μ g/mL actinomycin D (Sigma) 1 h before the addition of romidepsin.

Semiquantitative Reverse Transcription-PCR

Total RNA was isolated using the Trizol reagent (Invitro-gen). RNA (1 μ g) was reverse transcribed using PowerScript Reverse Transcriptase (Clontech). Amplification of cDNA was done using primers specific for *ABCG2*: 5'-CAATGGGAT-CATGAAACCTG-3' (forward) and 5'-GAGGCTGATGAATG-GAGAA-3' (reverse), *MDR-1*: 5'-CAGACAGCAGCTG-AGAGTCCAAGAACAGGACT-3' (forward) and 5'-GCCTG-GCAGCTGGAAGACAAATACACAAAATT-3' (reverse); and *GAPDH*: 5'-ACCACAGTCCATGCCATCAC-3' (forward) and 5'-TCCACCACCCTGTTGCTGTA-3' (reverse). Amplification of *GAPDH* cDNA served as an internal control. PCR amplification was done at an annealing temperature of 55°C for 28 cycles (*ABCG2*), 25 cycles (*GAPDH*), or 30 cycles (*MDR-1*) to yield 584, 330, and 440 bp products, respectively. The PCR products were resolved on 2% agarose gel and stained with ethidium bromide. Gel images were captured and the band intensity was quantitated by using the APP_Collage PPC4.0 analysis software program.

Luciferase Reporter Assays

A series of human *ABCG2* promoter constructs with progressive deletions at the 5'-ends has been described previously (14). The *ABCG2* promoter/firefly luciferase fusion genes (200 ng DNA) were transfected in pairs of parental and resistant cells using Fugene 6 (Roche). The pGL3-Basic (promoterless) plasmid, encoding firefly luciferase (Promega), was used to determine the basal levels. In each experiment, the pHRG-Basic plasmid (50 ng), encoding Renilla luciferase (Promega), was cotransfected for normalization purposes. Luminescence was measured 48 h after transfection using the Dual-Luciferase Reporter Assay System (Promega). Reporter activity was normalized by calculating the ratio of firefly/Renilla

values. Each construct was tested in three independent transfections. Results were expressed as mean $\pm$ SD.

Acid Extraction of Histones

Core histone proteins were extracted from the cells according to guidelines recommended by Abcam, Inc. Histones were acid extracted for 16 h at 4°C by adding ice-cold 0.2 mol/L HCl (4×10^7 cells/mL), washed, and finally resuspended in 100 μ L of distilled water.

Western Blot Analysis

Whole-cell lysates prepared from S1 and its resistant subline S1MI80 were separated by SDS-PAGE and subjected to immunoblot analysis with the respective antibodies (AcH3, HDAC1, and HDAC2, Upstate; ABCG2, Kamiya Biomedical Company; and HDAC3, HDAC6, and HDAC8, Santa Cruz Biotechnology). The antigen-antibody complex was detected with ECL kit (Pierce) following manufacturer's protocol.

For the immunoblotting of histones, equal amounts of histones (2 μ g) were analyzed on a 16% SDS-PAGE gel and subjected to immunoblot analysis using antibodies against the various histone modifications [AcH3 (Lys 9,14; Ac-K9,14 H3), trimethylated histone H3 (Lys 4; Me₃-K4 H3), trimethylated histone H3 (Lys 9; Me₃-K9 H3), Upstate; and phosphorylated histone H3 (Ser-10; P-S10 H3), Abcam]. Multiple gels were run simultaneously for immunoblot analysis. Equal loading of samples was ascertained by immunoblotting with an anti-total histone H3 antibody (CT, pan, clone A3S; Upstate).

ChIP Assays

ChIP was done using a ChIP assay kit (Upstate Biotechnology) according to the manufacturer's instructions, with some modifications. Briefly, proteins were cross-linked with DNA in the cultured cells using 1% formaldehyde for 10 min at 37°C and quenched with 0.125 mol/L glycine for 5 min at room temperature. The cells were then rinsed in ice-cold PBS containing 5 mmol/L sodium butyrate (Sigma), scraped, and resuspended in a lysis buffer (Active Motif) with the addition of complete protease inhibitor cocktail (Roche). The DNA-protein complexes were sheared using an enzymatic shearing kit (Active Motif) under conditions that gave a range in DNA fragments from 200 to 600 bp, as determined by agarose gel electrophoresis. ChIP was then carried out overnight at 4°C with one of the following antibodies: AcH3 (Ac-K9,14 H3), AcH4 (Ac-K5,8,12,16 H4), HDAC1, HDAC8 (Upstate), RNA Pol II, HDAC2, HDAC3, HDAC6, p300/CBP, GCN5, brm-related gene 1 (Brg-1; Santa Cruz), Sp1, or cJUN (Active Motif). To examine the extent of histone modifications associated with the *ABCG2* promoter, ChIP assays were repeated using antibodies against the various modifications, Me₃-K4 H3, Me₃-K9 H3, and P-S10 H3 (Upstate). Immunoprecipitated DNA was resuspended in 100 μ L of TE buffer. The amount of immunoprecipitated DNA was assessed by semi-quantitative PCR, using primers spanning the distal region (distal, nt -1,572 to -1,268) and proximal regions (P1, nt -687 to -579; P2, nt -428 to -271; P3, nt -293 to -139; and P4, nt -146 to +20) of the *ABCG2* promoter (Fig. 3A; ref. 14), and compared with the amount of input DNA before immunoprecipitation. Subregions within the proximal promoter (i.e., P1, P2, P3, or P4) were examined individually, although they cannot be precisely resolved by the ChIP assay, to show further the reproducibility of the analysis at the proximal promoter.

Amplification of the immunoprecipitated DNA was achieved using Taq DNA polymerase (Bioline) and 1 μ L of either immunoprecipitated DNA, a normal IgG control, or a 1:10 dilution of input chromatin. Experimental reactions were done to determine optimal PCR conditions so that the yield of PCR products was dependent on the amount of input DNA (data not shown). The conditions for the PCR reactions were as follows: 94°C for 3 min, 30

cycles at 94°C for 1 min, 55°C for 1 min, 72°C for 1 min, and a final extension at 72°C for 7 min. PCR products were electrophoresed on 2% agarose gel and stained with ethidium bromide. Band intensity was quantitated as mentioned above. Fold enrichment in each immunoprecipitation was determined by quantifying the intensities of the PCR product in immunoprecipitated DNA versus input DNA (total chromatin). Only 10% of the total input was used in the PCR reactions and they were run as the “input” lanes in gel electrophoresis. Percentage enrichment was calculated accordingly. ChIP assays were repeated thrice using different chromatin preparations.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Grant support: Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

References

1. Breedveld P, Beijnen JH, Schellens JH. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. *Trends Pharmacol Sci.* 2006; 27:17–24. [PubMed: 16337012]
2. Breedveld P, Zelcer N, Pluim D, et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles potential role for breast cancer resistance protein in clinical drug-drug interactions. *Cancer Res.* 2004; 64:5804–11. [PubMed: 15313923]
3. Maliepaard M, van Gastelen MA, Tohgo A, et al. Circumvention of breast cancer resistance protein (BCRP)-related resistance to camptothecins *in vitro* using non-substrate drugs or the BCRP inhibitor GF120918. *Clin Cancer Res.* 2001; 7:935–41. [PubMed: 11309344]
4. Van Herwaarden AE, Jonker JW, Wagenaar E, et al. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. *Cancer Res.* 2003; 63:6447–52. [PubMed: 14559835]
5. Allikmets R, Schriml LM, Hutchinson A, et al. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. *Cancer Res.* 1998; 58:5337–9. [PubMed: 9850061]
6. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. *Proc Natl Acad Sci U S A.* 1998; 95:15665–70. [PubMed: 9861027]
7. Maliepaard M, van Gastelen MA, de Jang LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected tumor cell line. *Cancer Res.* 1999; 59:4559–63. [PubMed: 10493507]
8. Miyake K, Mickley L, Litman T, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistance cells: demonstration of homology to ABC transport genes. *Cancer Res.* 1999; 59:8–13. [PubMed: 9892175]
9. Robey R, Medina-Perez WY, Nishiyama K, et al. Overexpression of the ATP-binding cassette half transporter, ABCG2 (Mxr/BCrp/ABCP1) in flavopiridol-resistant human breast cancer cells. *Clin Cancer Res.* 2001; 7:145–52. [PubMed: 11205902]
10. Volk EL, Farley KM, Wu Y, et al. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. *Cancer Res.* 2002; 62:5035–40. [PubMed: 12208758]
11. Ee PL, Kamalakaran S, Tonetti D, et al. Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. *Cancer Res.* 2004; 64:1247–51. [PubMed: 14973083]
12. Krishnamurthy P, Ross DD, Nakanishi T, et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. *J Biol Chem.* 2004; 279:24218–25. [PubMed: 15044468]

13. Szatmari I, Vamosi G, Brazda P, et al. Peroxisome proliferator-activated receptor γ -regulated ABCG2 expression confers cytoprotection to human dendritic cells. *J Biol Chem.* 2006; 281:23812–23. [PubMed: 16785230]
14. To KKW, Zhan Z, Bates SE. Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. *Mol Cell Biol.* 2006; 26:8572–85. [PubMed: 16954373]
15. Robey RW, Zhan Z, Piekaz RL, et al. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). *Clin Cancer Res.* 2006; 12:1547–55. [PubMed: 16533780]
16. Berger SL. Histone modifications in transcriptional regulation. *Curr Opin Genet Dev.* 2002; 12:142–8. [PubMed: 11893486]
17. Cosma MP. Ordered recruitment: gene-specific mechanism of transcription activation. *Mol Cell.* 2002; 10:227–36. [PubMed: 12191469]
18. Narlikar GJ, Fan HY, Kingston RE. Cooperation between complexes that regulate chromatin structure and transcription. *Cell.* 2002; 108:475–87. [PubMed: 11909519]
19. Turner BM. Decoding the nucleosome. *Cell.* 1993; 75:5–8. [PubMed: 8402900]
20. Lemon B, Inouye C, King DS, et al. Selectivity of chromatin-remodeling cofactors for ligand-activated transcription. *Nature.* 2001; 414:924–8. [PubMed: 11780067]
21. Struhl K. Fundamentally different logic of gene regulation in eukaryotes and prokaryotes. *Cell.* 1999; 98:1–4. [PubMed: 10412974]
22. Sudarsanam P, Winston F. The Swi/Snf nucleosome-remodeling complexes and transcriptional control. *Trends Genet.* 2000; 16:345–51. [PubMed: 10904263]
23. Bailey-Dell KJ, Hassel B, Doyle LA, et al. Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. *Biochim Biophys Acta.* 2001; 1520:234–41. [PubMed: 11566359]
24. Kuo MH, Allis CD. *In vivo* crosslinking and immunoprecipitation for studying dynamic protein:DNA associations in a chromatin environment. *Methods.* 1999; 19:425–33. [PubMed: 10579938]
25. Savickiene J, Treigyte G, Borutinskaite V, Navakauskiene R, Magnusson KE. The histone deacetylase inhibitor FK228 distinctly sensitizes the human leukemia cells to retinoic acid-induced differentiation. *Ann N Y Acad Sci.* 2006; 1091:368–84. [PubMed: 17341629]
26. Wang Q, Wang CM, Ai JS, et al. Histone phosphorylation and pericentromeric histone modifications in oocyte meiosis. *Cell Cycle.* 2006; 5:1974–82. [PubMed: 16969090]
27. Robbins AR, Jablonski SA, Yen TJ, et al. Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. *Cell Cycle.* 2005; 4:717–26. [PubMed: 15846093]
28. Bernstein BE, Humphrey EL, Erlich RL, et al. Methylation of histone H3 Lys 4 in coding regions of active genes. *Proc Natl Acad Sci U S A.* 2002; 99:8695–700. [PubMed: 12060701]
29. Lachner M, Jenuwein T. The many faces of histone lysine methylation. *Curr Opin Cell Biol.* 2002; 14:286–98. [PubMed: 12067650]
30. Liang G, Lin JC, Wei V, et al. Distinct localization of histone H3 acetylation and H3-4 methylation to the transcription start sites in the human genome. *Proc Natl Acad Sci U S A.* 2004; 101:7357–62. [PubMed: 15123803]
31. Nowak SJ, Corces VG. Phosphorylation of histone H3 correlates with transcriptionally active loci. *Genes Dev.* 2000; 14:3003–13. [PubMed: 11114889]
32. Santos-Rosa H, Schneider R, Bannister AJ, et al. Active genes are tri-methylated at K4 of histone H3. *Nature.* 2002; 419:407–11. [PubMed: 12353038]
33. Strahl BD, Ohba R, Cook RG, et al. Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in *Tetrahymena*. *Proc Natl Acad Sci U S A.* 1999; 96:14967–72. [PubMed: 10611321]
34. Bannister AJ, Zegerman P, Partridge JF, et al. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. *Nature.* 2001; 410:120–4. [PubMed: 11242054]
35. Peters AH, Mermoud JE, O'Carroll D, et al. Histone H3 lysine 9 methylation is an epigenetic imprint of facultative heterochromatin. *Nat Genet.* 2002; 30:77–80. [PubMed: 11740497]

36. Rice J, Briggs S, Ueberheide B, et al. Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains. *Mol Cell*. 2003; 12:1591–8. [PubMed: 14690610]
37. Mariadason JM, Corner GA, Augenlicht LH. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. *Cancer Res*. 2001; 60:4561–72. [PubMed: 10969808]
38. Morrow CS, Nakagawa M, Goldsmith ME, et al. Reversible transcriptional activation of *mdr1* by sodium butyrate treatment of human colon cancer cells. *J Biochem*. 1994; 269:10739–46.
39. Tabe Y, Konopleva M, Contractor K, et al. Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ARA in acute promyelocytic leukemia cells. *Blood*. 2006; 107:1546–54. [PubMed: 16223781]
40. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. *Mol Cancer Ther*. 2003; 2:151–3. [PubMed: 12589032]
41. Lee CK, Shibata Y, Rao B, et al. Evidence for nucleosome depletion at active regulatory regions genome-wide. *Nat Genet*. 2004; 36:900–5. [PubMed: 15247917]
42. Reinke H, Horz W. Histones are first hyperacetylated and then lose contact with the active PHO5 promoter. *Mol Cell*. 2003; 11:1599–607. [PubMed: 12820972]
43. Knutsen T, Rao VK, Ried T, et al. Amplification of 4q21-22 and the MXR gene in independently derived mitoxantrone-resistant cell lines. *Genes Chromosomes Cancer*. 2000; 27:110–6. [PubMed: 10564593]
44. Nakanishi T, Bailer-Dell KJ, Hassel BA, et al. Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage. *Cancer Res*. 2006; 66:5007–11. [PubMed: 16707421]
45. Huff LM, Lee JS, Robey RW, Fojo T. Characterization of gene rearrangements leading to activation of MDR-1. *J Biol Chem*. 2006; 281:36501–9. [PubMed: 16956878]
46. Doetzelhofer A, Rotheneder H, Lagger G, et al. Histone deacetylase 1 can repress transcription by binding to Sp1. *Mol Cell Biol*. 1999; 19:5504–11. [PubMed: 10409740]
47. Ashburner BP, Westerheide SD, Baldwin AS Jr. The p65 (RelA) subunit of NF- κ B interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. *Mol Cell Biol*. 2001; 21:7065–77. [PubMed: 11564889]
48. Chen KG, Wang YC, Schaner ME, et al. Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. *Cancer Res*. 2005; 65:9388–97. [PubMed: 16230402]
49. Baker EK, Johnstone RW, Zalberg JR, El-Osta A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. *Oncogene*. 2005; 24:8061–75. [PubMed: 16091741]
50. Grunstein M. Histone acetylation in chromatin structure and transcription. *Nature*. 1997; 389:349–52. [PubMed: 9311776]
51. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. *Genes Dev*. 1998; 12:599–606. [PubMed: 9499396]
52. Aglioti T, Chen G, Thanos D. Deciphering the transcriptional histone acetylation code for a human gene. *Cell*. 2002; 111:381–92. [PubMed: 12419248]
53. Kouzarides T. Histone methylation in transcriptional control. *Curr Opin Genet Dev*. 2002; 12:198–209. [PubMed: 11893494]
54. Richards EJ, Elgin SC. Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects. *Cell*. 2002; 108:489–500. [PubMed: 11909520]
55. Strahl BD, Allis CD. The language of covalent histone modifications. *Nature*. 2000; 403:41–5. [PubMed: 10638745]
56. Hake SB, Xiao A, Allis CD. Linking the epigenetic 'language' of covalent histone modifications to cancer. *Br J Cancer*. 2004; 90:761–9. [PubMed: 14970850]

57. Kouskouti A, Talianidis I. Histone modifications defining active genes persist after transcriptional and mitotic inactivation. *EMBO J.* 2005; 24:347–57. [PubMed: 15616580]
58. Yan C, Boyd DD. Histone H3 acetylation and H3 K4 methylation define distinct chromatin regions permissive for transgene expression. *Mol Cell Biol.* 2006; 26:6357–71. [PubMed: 16914722]
59. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. *Gene Expr.* 1996; 5:245–53. [PubMed: 8723390]
60. Mariadason JM, Corner GA, Augenlicht LH. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. *Cancer Res.* 2000; 60:4561–72. [PubMed: 10969808]
61. Johnstone R. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. *Nat Rev Drug Discov.* 2002; 1:287–99. [PubMed: 12120280]
62. Piekarz RL, Robey RW, Zhan ZR, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. *Blood.* 2004; 103:4636–43. [PubMed: 14996704]
63. Weiser TS, Guo ZS, Ohnmacht GA, et al. Sequential 5-aza-2'-deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytotoxic T lymphocytes specific for NY-ESO-1. *J Immunother.* 2001; 24:151–61. [PubMed: 11265773]
64. Kitazono M, Robey R, Zhan ZR, et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na^+/I^- symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. *J Clin Endocrinol Metab.* 2001; 86:3430–5. [PubMed: 11443220]

FIGURE 1.

Overexpression of ABCG2 in drug-selected resistant cell lines. Top, semiquantitative reverse transcription-PCR analysis of *ABCG2* in S1, MCF-7, H460, SF295 parental cells (P) and their respective resistant sublines (R) S1MI80, MCF-7 FLV1000, H460 MX20, SF295 MX2000, respectively. Bottom, immunoblot analysis of ABCG2 protein expression in the parental and resistant sublines as above.

FIGURE 2.

Transcriptional up-regulation of *ABCG2* by HDAC inhibition. **A** and **B**. Dose-dependent up-regulation of *ABCG2* in S1 cells after treatment with romidepsin (2, 5, 10, 20, or 30 ng/mL) for 24 h as measured by reverse transcription-PCR analysis (**A**) and immunoblot analysis (**B**). Global levels of AcH3 and AcH4 were increased upon romidepsin treatment, which seem saturated even after the lowest dose of romidepsin used (i.e., 2 ng/mL). The levels of AcH3 and AcH4 in the resistant S1MI80 cells were found to be similar to that in the parental S1 cells. *GAPDH* and rRNA expression was used as controls. **C**. Reverse transcription-PCR analysis of the up-regulation of *ABCG2* in S1 cells by romidepsin with or without a 4-h pretreatment of actinomycin D (5 µg/mL).

FIGURE 3.

ABCG2 chromatin was enriched with ACh3 in resistant S1MI80 cells and romidepsin-treated S1 cells. **A.** A schematic representation of the *ABCG2* promoter studied by ChIP analysis. Five sets of PCR primers, designated as Distal, P1, P2, P3, and P4, were used for amplification of the distal and proximal *ABCG2* promoter, respectively. Nucleotide positions are numbered relative to the major transcription start site (+1) defined in the published DNA sequence (Genbank accession no. AF151530). Big arrowhead, transcription start site. **B.** ChIP analyses targeting the proximal P1 to P4 and the distal region of the *ABCG2* promoter in parental S1, romidepsin-treated (20 ng/mL 24 h) S1, and resistant S1MI80 cells, using antibodies against ACh3 (K9,14) and ACh4 (K5,8,12,16). ACh3 and ACh4 enrichment at the *GAPDH* promoter was used as a control. Input, DNA isolated from the lysate before immunoprecipitation (only 10% of the total chromatin was used for the PCR reactions and it was run as the “input” in gel electrophoresis); IgG, ChIP using normal IgG for immunoprecipitation. **C.** parental S1; Dp, romidepsin-treated S1; R, resistant S1MI80 cells. Although the ChIP assay developed did not have sufficient resolution for assigning histone modifications to subregions within the proximal promoter (i.e., P1, P2, P3, or P4), the subregions were separately analyzed to ascertain the reproducibility of the assay. Importantly, the findings from the proximal regions are consistently different from the distal region (>1 kb apart). **C.** Quantitative analyses of the occupancy of ACh3 and ACh4 in

different regions of the *ABCG2* promoter in the ChIP assays in **B**. The results are expressed as the percentage of immunoprecipitate (*IP*) over total input DNA. Bars, SDs of three independent experiments.

FIGURE 4.

The proximal *ABCG2* promoter is associated with more AcH3 and RNA Pol II but less class I HDACs (HDAC1 and HDAC3). **A.** ChIP analyses targeting the proximal P3 and the distal regions of the *ABCG2* promoter in parental S1, romidepsin-treated S1, and resistant S1MI80 cells, using antibodies against AcH3 (K9,14), RNA Pol II, HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, GCN5, and p300. The *GAPDH* promoter was used as a control. **B.** Quantitative analyses of the occupancy of AcH3, Pol II, HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, GCN5, and p300 to the *ABCG2* promoter (P3 and distal region) and the *GAPDH* promoter in the ChIP assays in **A**. The results are expressed as the percentage of immunoprecipitate over total input DNA. Bars, SDs of three independent and reproducible experiments. **C.** Immunoblot analysis of the cellular level of AcH3, ABCG2, HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, GCN5, and p300 in the parental S1, romidepsin-treated S1, and S1MI80 cells. GAPDH was used as a loading control. The three treatment

groups expressed similar levels of all HDACs and HATs examined. HDAC inhibition by romidepsin results in hyperacetylation of H3 in the treated S1 cells. No appreciable global histone acetylation was observed in the resistant S1MI80 cells.

FIGURE 5.

Global and *ABCG2* promoter-specific histone modifications in resistant S1MI80 and romidepsin-treated parental S1 cells. **A.** Immuno-blot analysis of the cellular expression of the various modified forms of histone H3. Histone was extracted from the cells for immunoblot analysis. Equal loading of histones was ascertained by immunoblotting using anti-total H3 antibody. HDAC inhibition by romidepsin resulted in a robust hyperacetylation of H3 in the histone extracts. **B.** ChIP analyses targeting the proximal P3 region of the *ABCG2* promoter or the *GAPDH* promoter in parental S1, romidepsin-treated S1, and resistant S1MI80 cells, using antibodies against Ac-K9,14 H3, Me₃-K4 H3, Me₃-K9 H3, and P-S10 H3. **C.** Quantitative analyses of the association of the various modified forms of histone H3 at the proximal *ABCG2* promoter as in **B.** The results are expressed as the percentage of immunoprecipitate over total input DNA. Bars, SDs of three independent experiments.

FIGURE 6.

Romidepsin treatment did not augment the *ABCG2* expression in all cell types. Dose-dependent effect of romidepsin treatment (2, 5, 10, 20, or 30 ng/mL for 24 h) on the *ABCG2* expression. *MDR1* was robustly up-regulated by romidepsin in all cell lines tested. *GAPDH* expression was used as a control.

FIGURE 7.

Histone modifications at the *ABCG2* promoter in a panel of drug-selected resistant and romidepsin-treated parental cells. **A.** Levels of Ac-K9,14 H3, Me₃-K4 H3, Me₃-K9 H3, and P-S10 H3 at the proximal *ABCG2* promoter (P3). ChIPs were done with the parental, romidepsin-treated parental, and the resistant cells. **B.** Quantitative analyses of the association of the various modified forms of histone H3 to the proximal *ABCG2* promoter by ChIP analysis in **A**. The results are expressed as the percentage of immunoprecipitate over total input DNA used. Bars, SDs of three independent experiments.

FIGURE 8.

Association of selected transcription factors or nuclear proteins to the *ABCG2* promoter upon romidepsin treatment. ChIP analyses targeting the proximal *ABCG2* promoter in parental cells with or without romidepsin treatment, using antibodies against RNA Pol II, Brg-1, HDAC1, Sp1, c-JUN, and GCN5. The results are expressed as the percentage of immunoprecipitate over total input DNA. Bars, SDs of three independent experiments. In cell lines (i.e., S1 and H460) where *ABCG2* can be up-regulated by romidepsin treatment, a greater association of Pol II and Brg-1 but a weaker binding of HDAC1 and Sp1 to the *ABCG2* proximal promoter was observed. The association of c-JUN and GCN5 with the promoter was not affected by romidepsin in all cell lines tested.

FIGURE 9.

A model for the up-regulation of *ABCG2* in multidrug-resistant cells by permissive histone modifications and recruitment of chromatin remodeling factor. In untreated parental cells, prominent association of the repressive histone mark, Me₃-K9 H3, with the *ABCG2* promoter locks the *ABCG2* expression at low levels. In resistant cells, the repressive marks are replaced by permissive histone marks, Ac-K9,14 H3, Me₃-K4 H3, and P-S10 H3, followed by the recruitment of a chromatin remodeling factor (Brg-1) and RNA Pol II, and the release of class I HDACs from the *ABCG2* promoter. The switch to an open chromatin configuration also occurs in a limited number of cell lines upon treatment with romidepsin, up-regulating the expression of *ABCG2*. However, in other cell lines where *ABCG2* is not affected by romidepsin treatment, the repressive histone mark Me₃-K9 H3 is retained, although more AcH3 (K9,14) are found binding to the promoter. HDACs and likely other corepressors remain bound to the promoter, suppressing the *ABCG2* expression. Co-Rep, corepressors; Co-Act, coactivators; TF, transcription factor.